Pharyngitis

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, Blood, International, Chronic obstructive pulmonary disease, Cough, Bromide, Common, Headache, Nose, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Urine, Medical Subject Headings, Marketing, Sinusitis, Agency, Pharyngitis, INN, Lower respiratory tract infection, Constipation, Infection, ATC, Pain, COPD, Blood, International, Chronic obstructive pulmonary disease, Bromide, Common, Headache, Nose, Cough, Language, Brain, FEV1, Periodic breathing, Mouth, Inhalation, Gestational sac, Heart, Inflammation, Wheeze, B cell, European Medicines Agency, Xerostomia, Select, Patient, Urinary tract infection, Safety, Anatomy, Muscarinic acetylcholine receptor, Throat, IIA, Umeclidinium bromide, Medical device

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Brineura, cerliponase alfa, Date of authorisation: 30/05/2017, Revision: 7, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Brain damage, Medical Subject Headings, Marketing, Traffic barrier, European Commission, Agency, INN, Risk, Fever, Lower respiratory tract infection, Metabolism, Infection, Movement, Allergy, ATC, International, European, Spinal cord, Disease, Nose, Language, Brain, Pharyngitis, Skull, Hypersensitivity, European Medicines Agency, TPP1, Select, CLN2, Safety, Anatomy, Medicine, Vomiting, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Brineura, cerliponase alfa, Date of authorisation: 30/05/2017, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Brineura, cerliponase alfa, Date of authorisation: 30/05/2017, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Marketing, INN, Risk, Leukopenia, Hypophosphatemia, Hypotension, Pneumonia, Potassium, Nausea, Cancer, Myenteric plexus, Infection, Anatomy, Cough, IIA, Multiple myeloma, Chills, Consciousness, Diarrhea, Fever, Fatigue, Bone marrow, ATC, Pharyngitis, Pain, Platelet, Disease, Nose, Edema, Neutrophil, Speech, Depression, Appetite, Writing, Lymphocyte, Safety, Water, Tachycardia, Anemia, Neurological disorder, Hypocalcemia, Sepsis, Hypokalemia, Patient, Medical Subject Headings, Febrile neutropenia, Lymphocytopenia, Cytokine release syndrome, International, Encephalopathy, Neutropenia, Blood, Language, Thrombocytopenia, Neurotoxicity, Select, Medicine, Vomiting, Upper respiratory tract infection, Headache, Hospital, BCMA, Confusion, European Medicines Agency, Cell, Medical device

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Protein, Agency, Pharyngitis, INN, ATC, Urinary tract infection, International, Cough, Cystic fibrosis, Sore throat, Ageing, Language, Literature, Pseudomonas aeruginosa, Catherine Disher, Lower respiratory tract infection, European Medicines Agency, Infection, Fibrosis, Select, Patient, Bacteria, Anatomy, IIA, Periodic breathing, Medical device

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, INN, B-cell lymphoma, Infection, ATC, Pharyngitis, Pneumonia, Pain, CD20, Hypertension, Capsule, International, Bleeding, European, Platelet, Disease, Nose, Neutropenia, Language, Mouth, Cancer, Chronic lymphocytic leukemia, Waldenström macroglobulinemia, Thrombocytopenia, Lymphocytosis, Death, Rituximab, CLL, Neutrophil, DSM-IV codes, European Medicines Agency, BTK, Growth, Select, Patient, Bruise, Time, Anatomy, Bone marrow, IIA, Macroglobulinemia, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Peripheral neuropathy, Diarrhea, Marketing, Zidovudine, European Commission, Protease, Pharyngitis, INN, Immune system, Heartburn, HIV/AIDS, Fatigue, Saquinavir, Darunavir, ATC, Depression, Itch, Ritonavir, AIDS, International, Capsule, Cough, European, Headache, Disease, CD4, Ageing, Body surface area, Blood, Sore throat, Nausea, Rash, Language, Mouth, Abdominal pain, Dizziness, Flushing, Infection, Food, Indigestion, HIV, Tablet, Chronic pain, Reproduction, Back pain, Select, Committee, Patient, Dysgeusia, Risk management, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Lopinavir, CHMP, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Patient, Medical Subject Headings, Quality of life, Fluticasone, Marketing, Sinusitis, Agency, INN, Fever, Lower respiratory tract infection, Immunoglobulin E, Allergy, ATC, Chronic pain, Pain, International, Headache, Ageing, Nose, Blood, Language, MITES, Pharyngitis, Swelling, Inflammation, Dizziness, Red, European Medicines Agency, Polyp (medicine), Select, Overalls, Anatomy, Arthralgia, IIA, Pollen, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Patient, Medical Subject Headings, Marketing, Cytokine, Protein, Human, INN, Infection, ATC, Pharyngitis, International, Nose, Language, Mouth, CPU socket, Inflammation, JAK, European Medicines Agency, Lower respiratory tract infection, PASI, Tablet, Select, Cell, Diagnosis, Janus kinase, TYK2, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023
Sale, Peptide, Infant, Abdominal pain, Headache, Triptorelin, Patient, Oxytocin, Ovulation, Water intoxication, Pharyngitis, Infection, Oxygen, Background, Amniotic fluid, Erectile dysfunction, Lethargy, Pharmacy, Vomiting, Placenta, Osteoporosis, Safety, Fertility, Argyreia nervosa, Asphyxia, Canada Border Services Agency, DIN, Pelvimetry, Uterine rupture, Nursing, Drug identification number, Toxemia, Health, Diarrhea, Bleeding, Health Canada, Nausea, Chronic pain, Plasma protein binding, Fetus, Allergy, Somnolence, Anaphylaxis, Endometriosis, Depression, Hormone, Risk, Constipation, History, Premature, Long QT syndrome, Stroke, Seizure, Pain, Natural product, Drug, Upper respiratory tract infection, NPN, Prostate cancer, Prescription drug, Pituitary gland, Dietary supplement

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.